Clinical Trial Update: Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This update reports a completed Phase 1/2 trial of enhanced CD33-targeted CAR T cells in relapsed or refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Enhanced CD33 CAR T cells (CD33-targeted CAR T cells)

Snippet

Sponsor: Beijing Boren Hospital | Conditions: Acute Myeloid Leukemia, Relapse Leukemia | Phase 1, Phase 2 | Status: COMPLETED